Abstract Library

#4363 61Cu-NODAGA-LM3 for the detection of neuroendocrine tumours: Preliminary results of the COPPER PET in NET trial, a randomised, crossover, readers blind, phase I/II non-inferiority study

Introduction: Currently approved PET tracers, Gallium-68 or Copper-64 labelled somatostatin receptor (SST) agonists (NETSPOT®, SOMAKIT® and Detecnet™), for imaging well-differentiated gastroenteropancreatic and bronchopulmonary neuroendocrine tumours (NET) have limitations. Radiolabelled SST antagonists offer superior imaging properties over agonists, and the combination with Copper-61, an unexplored PET isotope with a 3.33-hour half-life and favourable production characteristics, could be promising.

Conference:

Presenting Author: Nicolas G

Authors: Nicolas G, Chirindel A, Kaul F, Rommers N, Johayem A,

Keywords: Somatostatin Receptor PET/CT, Well-differentiated NEN, gastroenteropancreatic NET, bronchopulmonary NET, randomised controlled clinical trial, somatostatin receptor antagonist,

#1883 Utility of a Circulating NET mRNA Gene Signature for Defining Bronchopulmonary Neuroendocrine Neoplasia and Evaluating Disease Progression

Introduction: Bronchopulmonary NETs (BPNETs) exhibit indolent to aggressive behavior. Imaging, histology and biochemistry are limited in accurately defining malignancy or progression. A blood based NET multigene test is effective in diagnosing GEP-NET progression and therapy response.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Kidd M

Authors: Lewczuk A, Chung K, Kolasińska-Ćwikła A, Ćwikła J, Kidd M,

Keywords: NET,

#1571 Blood Gene Transcript Analysis Diagnoses Bronchopulmonary NETs and Identifies Progressive Disease

Introduction: Broncho-Pulmonary (BP) NETs are pulmonary neoplasms with indolent to aggressive behavior. Imaging, histology and biochemistry are limited in defining malignancy or progression

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Lewczuk A

Authors: Lewczuk A, Chung K, Kolasińska-Ćwikła A, Cwikła J, Kidd M,

Keywords: PCR,

#1205 Temozolomid-Based Therapy in GEP-and Bronchopulmonary NEN from a Multicentric Study from Germany

Introduction: Chemotherapy (CTx) with temozolomid as mono (TEM) or combination therapy with capcitabine (TEM/CAP) is a new cytotoxic regimen with good efficiency in pancreatic and bronchopulmonary NET-G1/G2 and NEC-G3.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Maasberg S, Bacher M, Rinke A, Lahner H, Unger N,

Keywords: temozolomide, capecitabine,

#1039 Receptor Tyrosine-Kinases Inhibition: New Insights on Therapeutic Implications of EGFR and IGF1R in Human Bronchopulmonary NET

Introduction: The main treatment for bronchopulmonary NET(BP-NET) is surgery, which is not feasible for infiltrating and metastatic disease, where medical therapy is tried. Identifying new therapeutic targets is important to provide adequate medical treatment for patients with BP-NET. Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor (TKI), is mainly described to inhibit VEGF

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Gagliano T

Authors: Gagliano T, Benfini K, Gentilin E, Falletta S, Di Pasquale C,

Keywords: RTK, BP-NET, IGF1R, EGFR,